Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Can Generic Drugs Be Repurposed for COVID-19 Treatment?
A Fight Against Obesity: Evaluating Clinical Data from the SURMOUNT-1 Trial
Heart Failure Consensus Report: A Review of ADA Recommendations
Exploring AACE Updates on the Management of NAFLD & NASH
The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone
Investigating Interventions: The Role of Lifestyle Changes in Preventing Diabetes
Exploring A New Anti-Obesity Treatment
Exploring the Deintensification of Hypoglycemia-Inducing Medications
Investigating the T1D Increase: A Look at Rising Rates in Children Amid COVID-19
Evaluating the Rapid Rise of T1D in Children Amid the COVID-19 Pandemic
Evaluating the Importance of Oral Health in T1D
Key Communication Strategies for Patients with Diabetes
Diabetes Alert Day: Spreading Awareness & Education
Hospitalization Utilization & Communication in Hypoglycemia: An Inside Look at Emerging Data
A Look at Emerging Research on T2D & COVID-19 Severity
Improving Diabetes Care with Positive Experience & Peer Support
Dissecting Diabetes: Key Considerations for Low Protein Intake
Hypoglycemia & the Cardiovascular System: An Inside Look at Emerging Clinical Trial Data
Exploring Experimental Medicine Studies, the Risk of Thrombosis, & the Impacts of Hypoglycemia
Assessing Glucose Control & Reducing Cardiovascular Risk in Patients with Diabetes
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video